000101269 001__ 101269
000101269 005__ 20180317093132.0
000101269 0247_ $$2doi$$a10.1002/jnr.10434
000101269 022__ $$a0360-4012
000101269 02470 $$2DAR$$a961
000101269 02470 $$2ISI$$a000179541900004
000101269 037__ $$aARTICLE
000101269 245__ $$aGlial cell line-derived neurotrophic factor released by synthetic guidance channels promotes facial nerve regeneration in the rat
000101269 260__ $$c2002
000101269 269__ $$a2002
000101269 336__ $$aJournal Articles
000101269 500__ $$aDepartment of ENT and Head and Neck Surgery, University Medical School, Lausanne, Switzerland.
000101269 520__ $$aRegeneration of the human facial nerve after lesion is often limited, leading to severe functional impairments, in particular when repair is delayed for several months, when cross-facial nerve grafts have to be performed, or in elderly patients. To improve the outcome, the potential accelerating and maturating effects of the neurotrophic factors glial cell line-derived neurotrophic factor (GDNF) and neurotrophin-3 (NT-3) on nerve regeneration were assessed using an axotomy model of the rat facial nerve. One-centimeter-long synthetic guidance channels releasing the neurotrophic factors over several weeks were used to bridge an 8 mm nerve gap, a distance that does not allow regeneration in the absence of growth factors. Nerve cables regenerated in the presence of GDNF showed a large number of myelinated axons 6 weeks after grafting (871 +/- 373, n = 5), whereas only 106 +/- 86 (n = 5) myelinated axons were counted in the presence of NT-3. Retrograde labeling with fluorogold revealed 981 +/- 450 (n = 5) and 53 +/- 38 (n = 5) retrogradely labeled motoneurons in the facial nucleus in the presence of GDNF and NT-3, respectively. No regenerated axons or retrogradely labeled cells were observed in the absence of growth factors (n = 6). These results demonstrate that GDNF, as previously described for the sciatic nerve, a mixed sensory and motor nerve, is also very efficient in promoting regeneration of the facial nerve, an essentially pure motor nerve. GDNF may therefore be useful in improving facial nerve regeneration in the clinic.
000101269 6531_ $$aAnimals
000101269 6531_ $$aAxons/drug effects/pathology
000101269 6531_ $$aAxotomy
000101269 6531_ $$aFacial Nerve/ drug effects/pathology/surgery
000101269 6531_ $$aGlial Cell Line-Derived Neurotrophic Factor
000101269 6531_ $$aImplants
000101269 6531_ $$aExperimental
000101269 6531_ $$aMale
000101269 6531_ $$aMotor Neurons/drug effects
000101269 6531_ $$aNerve Fibers
000101269 6531_ $$aMyelinated/drug effects/pathology
000101269 6531_ $$aNerve Growth Factors/ administration & dosage/pharmacology
000101269 6531_ $$aNerve Regeneration/ drug effects
000101269 6531_ $$aNeurotrophin 3/ administration & dosage/pharmacology
000101269 6531_ $$aPolyvinyls
000101269 6531_ $$aRats
000101269 6531_ $$aRats
000101269 6531_ $$aWistar
000101269 6531_ $$aRats
000101269 700__ $$aBarras, F. M.
000101269 700__ $$aPasche, P.
000101269 700__ $$0241464$$aBouche, N.$$g150219
000101269 700__ $$0240206$$aAebischer, P.$$g104359
000101269 700__ $$aZurn, A. D.
000101269 773__ $$j70$$k6$$q746-55$$tJ Neurosci Res
000101269 909CO $$ooai:infoscience.tind.io:101269$$particle$$pSV
000101269 909C0 $$0252067$$pLEN$$xU10457
000101269 937__ $$aLEN-ARTICLE-2002-006
000101269 970__ $$a48/LEN
000101269 973__ $$aEPFL$$rREVIEWED$$sPUBLISHED
000101269 980__ $$aARTICLE